Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Low-dose colestipol plus probucol for hypercholesterolemia.

C A Dujovne, S B Chernoff, P Krehbiel

    The American Journal of Cardiology
    |June 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Measurement of the centrality dependence of the charged-particle pseudorapidity distribution in proton-lead collisions at [Formula: see text] TeV with the ATLAS detector.

    The European physical journal. C, Particles and fields·2017
    Same author

    Measurement of the Inelastic Proton-Proton Cross Section at sqrt[s]=13  TeV with the ATLAS Detector at the LHC.

    Physical review letters·2016
    Same author

    Search for Higgs and Z Boson Decays to ϕγ with the ATLAS Detector.

    Physical review letters·2016
    Same author

    Acute photosensitisation and mortality in a herd of dairy cattle in Tasmania.

    New Zealand veterinary journal·2016
    Same author

    Identification of boosted, hadronically decaying <i>W</i> bosons and comparisons with ATLAS data taken at [Formula: see text] TeV.

    The European physical journal. C, Particles and fields·2016
    Same author

    Observation of Long-Range Elliptic Azimuthal Anisotropies in sqrt[s]=13 and 2.76 TeV pp Collisions with the ATLAS Detector.

    Physical review letters·2016
    Same journal

    Real-World Effectiveness and Tolerability of Sacubitril/Valsartan in Octogenarian Patients With Heart Failure: Results From the PARACHUTER Study.

    The American journal of cardiology·2026
    Same journal

    ECG-Guided Conduction Pathways as a Lever to Shorten Post-TAVI Hospitalization.

    The American journal of cardiology·2026
    Same journal

    Cystatin-C versus creatinine and kidney function in heart failure with preserved ejection fraction: a SOGALDI-PEF analysis.

    The American journal of cardiology·2026
    Same journal

    Balloon-expandable versus Self-expanding Valves in Patients with Small Aortic Annuli Undergoing Transcatheter Aortic Valve Replacement.

    The American journal of cardiology·2026
    Same journal

    Drug-Coated Balloons versus Drug-Eluting Stents following Coronary Atherectomy in Severely Calcified Lesions: A Systematic Review and Meta-Analysis.

    The American journal of cardiology·2026
    Same journal

    Prehospital Statin Therapy and Outcomes in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

    The American journal of cardiology·2026
    See all related articles

    Combining probucol with a reduced dose of colestipol effectively lowers LDL cholesterol. This combination therapy offers improved tolerability and significant reductions in cholesterol levels for hypercholesterolemic patients.

    Area of Science:

    • Cardiology
    • Pharmacology
    • Metabolic Disorders

    Background:

    • Hypercholesterolemia poses a significant risk for cardiovascular diseases.
    • Current treatments, like colestipol, can have dose-limiting side effects.
    • Alternative or combination therapies are needed to improve efficacy and tolerability.

    Purpose of the Study:

    • To compare the efficacy and adverse effects of colestipol alone versus a combination of probucol and a reduced dose of colestipol.
    • To evaluate the impact of combination therapy on lipid profiles and patient tolerability.

    Main Methods:

    • A 19-month, double-placebo, diet-controlled crossover trial involving 22 hypercholesterolemic patients.
    • Patients received either colestipol (20 g/day) or a combination of probucol (1 g/day) and colestipol (10 g/day).

    Related Experiment Videos

  • Diet and physical activity were standardized; LDL cholesterol levels were monitored.

    • Main Results:

    • The combination therapy (probucol + half-dose colestipol) achieved significant LDL cholesterol reduction, comparable to full-dose colestipol alone.
    • Fifteen patients experienced the greatest LDL cholesterol reduction with the combined therapy.
    • Probucol significantly reduced VLDL and HDL cholesterol; gastrointestinal side effects were ameliorated with combination therapy.

    Conclusions:

    • Co-administration of probucol with a 50% reduced dose of colestipol is effective in lowering LDL cholesterol.
    • This combination therapy offers improved tolerability and efficacy, rarely seen with other hypocholesterolemic treatments.
    • Patients intolerant to full-dose resins may benefit equally from a reduced dose combined with probucol.